Redeye comments on 2cureX’s Q1 report, reiterating our positive view of the company. During the quarter, 2cureX announced that the TICC trial reached its primary endpoint. Proof-of-concept in hand, 2cureX is now executing IndiTreat commercialization and expects first sales during H2 2021.